We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




bioMérieux Acquires Microbial Genotyping Technology

By Labmedica staff writers
Posted on 03 Oct 2006
bioMérieux (Marcy-l'Etoile, France), a company specializing in in vitro diagnostics, has acquired Bacterial Barcodes (BBCI, Athens, Georgia, USA). More...
The financial terms of the acquisition were not disclosed.

BBCI is a molecular biotechnology company that developed and markets DiversiLab, a system dedicated to the field of automated microbial genotyping, offering solutions to track hospital-acquired infections (HAI) and for environmental control for product safety.

The technology automates the previously cumbersome method of strain typing and allows for better genotypic characterization of bacteria, yeast, and fungi, which helps identify the source and stop the spread of further infection. DiversiLab complements the bioMérieux suite of solutions, and together they support clinical decisions that may ultimately reduce HAIs and support the prudent usage of antibiotics.

The DiversiLab system eliminates complex manual laboratory procedures for determining the source of infections and contamination. DiversiLab allows healthcare practitioners and quality control/assurance departments to conduct investigations up to 10 times faster than previous methods. The system consists of web-based software for detection and analysis, and quality-controlled DNA fingerprinting kits (or reagents).

The technology is focused on the rapid identification of outbreak and contamination source tracking and is applicable in the hygiene market for tracking antibiotic resistant microorganisms causing hospital-acquired infections and in industrial markets for food, agricultural, pharmaceutical, and environmental contamination testing. It is also useful for characterizing biothreat agents and identifying potential outbreaks in the biodefense market.

"We are excited about the opportunity to join the industry leader in the field of infectious disease diagnostics and infection control and we feel positive about the impact our solutions can have in both the healthcare and industrial markets,” said Mimi Healy, Ph.D., president and CEO, BBCI. "The DiversiLab system perfectly complements bioMerieux's technology portfolio, which will help discriminate and track the spread and source of bacterial infections and contamination more quickly, more accurately, and more cost-effectively than other systems on the market today.”



Related Links:
bioMérieux
Bacterial Barcodes

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.